Can a quick dose of dapagliflozin help elderly heart failure patients in the ER?

NCT ID NCT07392788

Not yet recruiting Disease control Sponsor: Centre Hospitalier Universitaire de Besancon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether starting the drug dapagliflozin within 24 hours of arriving at the emergency room is practical for elderly patients (75+) with acute heart failure. It will involve 144 patients across 6 hospitals, comparing early drug treatment plus a nurse phone call to standard care alone. The main goal is to see if the process works smoothly, not yet to measure health benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin (a type of SGLT2 inhibitor drug)
What this could lead to: If successful, this could show that starting dapagliflozin early in the emergency room is practical for elderly heart failure patients, potentially leading to better outcomes.
What could go wrong: This is a small pilot study focused on feasibility, not effectiveness. It may not prove that early treatment improves health, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE DECOMPENSATED CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure Emergencies heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE HEART FAILURE (AHF)

More trials for these conditions

Other studies related to the condition(s) this trial covers.